Farmak’s specialists have developed L’esfal hepatoprotective drug of broad use spectrum and introduced it to the market. A new product is released in form of solution for injections.
L’esfal contains essential phospholipids (1 ml solution contains phosphatidylcholine out of soybeans 50 mg), needed to recover the structure and functions of the liver cells.
Kateryna Myrgorodska, Farmak’s Product Manager of OTC Drugs Marketing Department: “L’esfal is prescribed for the treatment of acute and chronic hepatitis, cirrhosis, fat and alcoholic liver disease, toxicosis in pregnant women and dermatological diseases.
The drug not only protects the liver from different destructive effects but recovers its affected structure. It should be noted that L’esfal may be prescribed for the children aged 12 years and older and pregnant and breast-feeding women”.
TOP 100. The Ratings of the Largest published the Employer Brand Rating and the Rating of TOP 30 Best HR Directors in Ukraine. According to the magazine, Farmak is one of three companies providing the best working conditions, and Viktoria Kondrashykhina, HR Director of Farmak, became the best HR director in the pharmaceutical industry. The […]
CEO of Farmak took part in a panel discussion during Kyiv Investment Forum “Local Business Development: from manufacturer to end consumer” and presented the components of successful business Paolo Di Croce, Secretary General of Slow Food International, Olha Mahaletska, Head of the Office of the National Investment Council, Iryna Danylevska, UFW Founder &...
The teams of Farmak, Alfa-Bank Ukraine, DTEK, Energoatom, FUIB, Astarta-Kyiv, EPAM, EY Ukraine, FILM.UA Group presented their projects of Integration of Sustainable Development Goals in existing business models at the final event of the international Young SDG Innovators Programme launched by the UN Global Compact. The event gathered together 148 team...